GlaxoSmithKline tuberculosis vaccine shows promise in phase 2b

It’s been a nearly a century since the development of the world’s only tuberculosis vaccine, and Tuesday GlaxoSmithKline and its nonprofit partner Aeras touted early results for what could be a promising vaccine against a deadly disease.